Vertex Pharmaceuticals Incorporated : Vertex and Crispr to market $2.2 million treatment for sickle cell disease

The first treatment was developed by Vertex Pharmaceuticals and Crispr Therapeutics. Casgevy will be sold in the USA for $2.2 million. But this amount must be set against the current cost of care, estimated at between $4 and $6 million over the lifetime of patients, according to the treatment’s prom…
© MarketScreener.com 2023